Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Ryan

Showing results (111-120 of 274) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumorsAndrew X Zhu, Neal Ready, Jeffrey W Clark, et al.
Digestive Diseases and Sciences|January 18, 2006
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinomaPeter C Enzinger, Matthew H Kulke, Jeffrey W Clark, et al.
The Oncologist|December 20, 2002
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumorsDavid P Ryan, Thomas Puchalski, Jeffrey G Supko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancerJeffrey A Meyerhardt, Andrew X Zhu, Peter C Enzinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumorsMatthew H Kulke, Jason L Hornick, Christine Frauenhoffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
MDM2 promoter polymorphism and pancreatic cancer risk and prognosisKofi Asomaning, Amy E Reid, Wei Zhou, et al.
International Journal of Radiation Oncology, Biology, Physics|June 5, 2007
Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatmentKevin R Kozak, Lisa A Kachnic, Judith Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin, Aram F Hezel, Thomas Abrams, et al.
European Radiology|October 13, 2021
Response prediction of neoadjuvant chemoradiation therapy in locally advanced rectal cancer using CT-based fractal dimension analysisToru Tochigi, Sophia C Kamran, Anushri Parakh, et al.
International Journal of Radiation Oncology, Biology, Physics|April 28, 2010
Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the headTheodore S Hong, David P Ryan, Lawrence S Blaszkowsky, et al.
Pageof 28

Showing results (111-120 of 274) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumorsAndrew X Zhu, Neal Ready, Jeffrey W Clark, et al.
Digestive Diseases and Sciences|January 18, 2006
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinomaPeter C Enzinger, Matthew H Kulke, Jeffrey W Clark, et al.
The Oncologist|December 20, 2002
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumorsDavid P Ryan, Thomas Puchalski, Jeffrey G Supko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancerJeffrey A Meyerhardt, Andrew X Zhu, Peter C Enzinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumorsMatthew H Kulke, Jason L Hornick, Christine Frauenhoffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
MDM2 promoter polymorphism and pancreatic cancer risk and prognosisKofi Asomaning, Amy E Reid, Wei Zhou, et al.
International Journal of Radiation Oncology, Biology, Physics|June 5, 2007
Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatmentKevin R Kozak, Lisa A Kachnic, Judith Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin, Aram F Hezel, Thomas Abrams, et al.
European Radiology|October 13, 2021
Response prediction of neoadjuvant chemoradiation therapy in locally advanced rectal cancer using CT-based fractal dimension analysisToru Tochigi, Sophia C Kamran, Anushri Parakh, et al.
International Journal of Radiation Oncology, Biology, Physics|April 28, 2010
Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the headTheodore S Hong, David P Ryan, Lawrence S Blaszkowsky, et al.
Pageof 28